Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TTRX | 8-K | bullish | 5/10 | Turn Therapeutics announced a peer-reviewed publication in the Journal of Dermatological Treatment showing that GX-03 ac | Jun 5, 2026 |
| SVA | 20-F | bearish | 8/10 | Sinovac filed its long-delayed FY2025 annual report (20-F) on June 5, 2026, just days after receiving a Nasdaq delist no | Jun 5, 2026 |
| EDSA | 8-K | bullish | 7/10 | Edesa Biotech reported exploratory data for paridiprubart in acute kidney injury (AKI) patients at the ERA Congress. In | Jun 5, 2026 |
| PASG | 8-K | bearish | 6/10 | Passage Bio terminated its research collaboration with Gemma Biotherapeutics for Huntington's disease and epilepsy progr | Jun 5, 2026 |
| EDSA | PRESS-RELEASE | bullish | 6/10 | Edesa Biotech reported favorable exploratory data for paridiprubart in acute kidney injury (AKI) patients with respirato | Jun 5, 2026 |
| NERV | 8-K | bearish | 6/10 | Minerva Neurosciences entered into an at-the-market (ATM) equity offering agreement with Leerink Partners to sell up to | Jun 5, 2026 |
| TLSA | 6-K | neutral | 3/10 | Tiziana Life Sciences filed a 6-K announcing its upcoming corporate presentation at the Jefferies Healthcare Conference | Jun 5, 2026 |
| BAK | 6-K | mixed | 7/10 | Braskem has closed a control-block share transaction where Shine I FIP acquired ~50.11% of voting shares from NSP Inv., | Jun 5, 2026 |
| NRXP | PRESS-RELEASE | bullish | 7/10 | NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ket | Jun 5, 2026 |
| PULM | 425 | neutral | 4/10 | Pulmatrix filed a Rule 425 communication on behalf of Eos SENOLYTIX, announcing preclinical data for PTC-2105 at the Sac | Jun 5, 2026 |
| EVMN | 144 | bearish | 5/10 | Gregory S. Moss, an officer of Evommune, filed a Form 144 on May 28, 2026, indicating intent to sell 14,223 shares of co | Jun 5, 2026 |
| IMVT | 144 | neutral | 3/10 | Director Andrew J. Fromkin filed a Form 144 on May 28, 2026, indicating intent to sell up to 221,951 shares of Immunovan | Jun 5, 2026 |
| CANF | 6-K | neutral | 2/10 | Can-Fite BioPharma's 2026 Annual General Meeting of Shareholders was adjourned due to lack of quorum and rescheduled for | Jun 5, 2026 |
| MBRX | 8-K | bullish | 5/10 | Moleculin Biotech announced results from an independent market landscape assessment for its lead drug Annamycin in relap | Jun 5, 2026 |
| CLRB | DEFA14A | neutral | 4/10 | Cellectar Biosciences filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting sched | Jun 5, 2026 |
| SAFX | 8-K | bearish | 6/10 | XCF Global raised $4M in gross proceeds via two private placements of 26.7M shares at $0.15/share, representing ~18% dil | Jun 5, 2026 |
| GNTA | 6-K | mixed | 6/10 | Genenta Science completed the acquisition of the remaining 80.5% of A.T.C. S.r.l. for €9.6M, paid via the issuance of 24 | Jun 5, 2026 |
| TSHA | PRESS-RELEASE | neutral | 2/10 | Taysha Gene Therapies granted 714,700 RSUs and an option for 468,600 shares to four new employees under its 2023 Inducem | Jun 5, 2026 |
| BCDA | 8-K | bullish | 6/10 | BioCardia announced FDA confirmation that its ongoing CardiAMP Heart Failure II trial may support a Premarket Approval ( | Jun 5, 2026 |
| MBX | 8-K | neutral | 3/10 | MBX Biosciences held its 2026 annual meeting on June 4, 2026, where stockholders elected Class II directors Patrick J. H | Jun 5, 2026 |
| CMND | PRESS-RELEASE | neutral | 2/10 | Clearmind Medicine announced a live webinar on June 10, 2026, featuring investigators from Yale and Johns Hopkins to dis | Jun 5, 2026 |
| LSTA | 8-K | bearish | 7/10 | Kuva Labs informed Lisata Therapeutics it will not commence the previously-agreed tender offer on June 1, 2026, citing o | Jun 5, 2026 |
| PSTV | S-3/A | neutral | 3/10 | Plus Therapeutics filed Pre-Effective Amendment No. 1 to its Form S-3 shelf registration (File No. 333-296411) as an exh | Jun 5, 2026 |
| CATX | 8-K | neutral | 3/10 | Perspective Therapeutics updated its corporate presentation on June 1, 2026, highlighting ASCO 2026 data for its 212Pb-b | Jun 5, 2026 |
| JBIO | 8-K | bullish | 7/10 | Jade Biosciences reported interim Phase 1 data for JADE101, an anti-APRIL antibody for IgAN. The data showed ~70% mean I | Jun 5, 2026 |
| CLYM | 8-K | neutral | 4/10 | Climb Bio announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL mo | Jun 5, 2026 |
| OTLK | 8-K | bullish | 7/10 | Outlook Therapeutics resubmitted its Biologics License Application (BLA) for ONS-5010/LYTENAVA (bevacizumab-vikg) to the | Jun 5, 2026 |
| LQDA | 144 | neutral | 4/10 | Director Arthur S. Kirsch filed a Form 144 notice of intent to sell 30,000 shares of Liquidia Corp common stock, with an | Jun 5, 2026 |
| MCRB | 8-K | mixed | 6/10 | Seres Therapeutics announced two balance-sheet-strengthening transactions: a $25M buyout of contingent VOWST milestones | Jun 5, 2026 |
| MCRB | PRESS-RELEASE | neutral | 5/10 | Seres Therapeutics announced a $25M buyout of future VOWST milestones from Nestlé Health Science and a lease restructuri | Jun 5, 2026 |